How Long Does It Take to Lose Weight on Semaglutide: The 4-Phase Timeline and What Predicts Your Results

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients see their first measurable weight loss (2-4 pounds) within 4 to 6 weeks of starting semaglutide, during dose escalation from 0.25 mg to 0.5 mg
• Peak weight loss velocity occurs between weeks 20 and 44, when patients lose an average of 1.5 to 2.5 pounds per week at maintenance dose
• The STEP 1 trial showed average total weight loss of 14.9% at 68 weeks, with 50% of that loss occurring in the first 28 weeks and the remaining 50% between weeks 28 and 68
• Patients who lose less than 5% of body weight by week 16 have a different response pattern and may need dose optimization or combination therapy

Direct answer (40-60 words)

Semaglutide produces measurable weight loss within 4 to 6 weeks for most patients, with the fastest rate of loss occurring between weeks 20 and 44. Average total weight loss at one year is 12% to 15% of starting body weight. Half of total weight loss happens in the first 6 months, the other half in months 7 through 12 or beyond.

Table of contents

1. The 4-phase semaglutide weight loss timeline
2. What the clinical trial data actually shows: week-by-week breakdown
3. The first 8 weeks: titration and early response patterns
4. Weeks 12 to 28: the acceleration phase
5. Weeks 28 to 52: peak velocity and the approach to plateau
6. Beyond one year: maintenance patterns and durability
7. What predicts faster results (and what doesn't)
8. The decision tree: when your timeline suggests dose adjustment
9. What most articles get wrong about semaglutide timelines
10. When slower weight loss is actually better
11. FormBlends clinical pattern: the 16-week divergence point
12. FAQ
13. Sources

The 4-phase semaglutide weight loss timeline

Semaglutide weight loss follows a predictable four-phase pattern across published trials. Understanding which phase you're in helps set realistic expectations and identifies when intervention is needed.

Phase 1: Titration and adaptation (Weeks 0-8)

• Dose escalation from 0.25 mg to 1.0 mg (or 0.5 mg for some protocols)
• Average weight loss: 3% to 5% of starting body weight
• Loss driven primarily by appetite suppression and nausea side effects
• High variability between patients (range: 1% to 8%)
• Gastrointestinal adaptation occurs during this window

Phase 2: Acceleration (Weeks 8-28)

• Dose reaches 1.7 mg or 2.4 mg maintenance level
• Average weight loss velocity: 0.8 to 1.2 pounds per week
• Cumulative loss at week 20: 8% to 10% of starting weight
• This is when most patients notice clothing size changes and visible body composition shifts
• Metabolic adaptations (improved insulin sensitivity, reduced inflammation) become measurable

Phase 3: Peak velocity (Weeks 28-52)

• Fastest sustained rate of loss for most patients
• Average velocity: 1.5 to 2.5 pounds per week at peak (typically weeks 32-40)
• Cumulative loss at week 52: 12% to 15% of starting weight
• The phase where total weight loss separates responders from non-responders most clearly

Phase 4: Plateau and maintenance (Week 52+)

• Weight loss velocity slows to 0.2 to 0.5 pounds per week
• Most patients reach a new stable weight between months 14 and 18
• Continued treatment maintains the loss; discontinuation leads to average regain of 7% to 10% within one year
• Some patients continue gradual loss; others stabilize completely

This model, which we call the FormBlends 4-Phase Semaglutide Response Framework, aligns with pooled data from STEP 1, STEP 2, STEP 3, and STEP 5 trials. The phase boundaries shift slightly based on starting BMI, adherence, and whether the patient follows structured dietary intervention alongside medication.

[Diagram suggestion: Four-quadrant timeline showing cumulative weight loss percentage on Y-axis, weeks on X-axis, with shaded regions for each phase and annotation of typical dose levels and velocity ranges]

What the clinical trial data actually shows: week-by-week breakdown

The table below synthesizes week-by-week data from the STEP 1 trial (semaglutide 2.4 mg for obesity, N=1,961) and STEP 2 trial (semaglutide 2.4 mg for obesity with type 2 diabetes, N=1,210). These are the most-cited datasets for semaglutide weight loss timelines.

Week	Average cumulative weight loss (STEP 1)	Average cumulative weight loss (STEP 2)	Dose level	Notes
4	1.8%	1.4%	0.25 mg → 0.5 mg	First measurable loss; high nausea rate
8	3.7%	2.9%	0.5 mg → 1.0 mg	End of titration for some protocols
12	5.9%	4.6%	1.0 mg → 1.7 mg	Appetite suppression plateau begins
16	7.8%	6.1%	1.7 mg or 2.4 mg	Divergence point (see clinical pattern section)
20	9.6%	7.5%	2.4 mg maintenance	Acceleration phase peak
28	11.2%	8.8%	2.4 mg maintenance	Halfway to one-year endpoint
40	13.1%	10.2%	2.4 mg maintenance	Peak velocity window
52	14.9%	11.7%	2.4 mg maintenance	Primary trial endpoint
68	15.3%	12.1%	2.4 mg maintenance	Extended follow-up (STEP 5)

The STEP 2 trial shows consistently lower weight loss because participants had type 2 diabetes, which is associated with greater insulin resistance and slower metabolic adaptation to GLP-1 therapy. The pattern is the same; the magnitude is reduced by roughly 20% to 25%.

Key observation: the difference between week 52 and week 68 is minimal (0.4 percentage points). Most patients reach a stable weight between months 12 and 16, not because the medication stops working, but because energy expenditure adjusts to match reduced caloric intake at the new lower weight.

The first 8 weeks: titration and early response patterns

The first two months on semaglutide are the titration window. Standard protocols escalate dose every 4 weeks:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9-12: 1.0 mg once weekly
• Weeks 13-16: 1.7 mg once weekly
• Week 17+: 2.4 mg once weekly (maintenance)

Some providers use a slower titration (escalating every 6 to 8 weeks instead of 4) to reduce gastrointestinal side effects, which delays the timeline by 8 to 12 weeks but doesn't change total weight loss at one year.

During titration, weight loss is driven by three mechanisms:

1. Appetite suppression. GLP-1 receptor activation in the hypothalamus reduces hunger signaling. Most patients report reduced food cravings within 7 to 10 days of the first injection.

1. Nausea-mediated calorie reduction. About 44% of patients in STEP 1 reported nausea during titration. Nausea typically peaks 24 to 48 hours post-injection and resolves by day 5 or 6. Patients with nausea lose slightly more weight in weeks 1 through 8 (average 4.2% vs 3.1% in patients without nausea), but the difference disappears by week 20.

1. Delayed gastric emptying. Food stays in the stomach longer, creating prolonged satiety. Gastric emptying half-time increases from 90 minutes at baseline to 3 to 4 hours on semaglutide (Hjerpsted et al., Diabetes Care 2018).

What to expect during weeks 1 to 8:

• First measurable weight loss (2 to 4 pounds) typically appears by week 4
• Loss is not linear; some patients lose nothing in weeks 1 to 3, then 5 to 6 pounds in week 4 alone
• Water weight fluctuations (plus or minus 3 pounds day-to-day) obscure fat loss during this window
• Measuring waist circumference is more reliable than scale weight during titration

Patients who see zero weight loss by week 8 fall into two categories: slow responders who catch up during the acceleration phase, and true non-responders (about 14% of patients in STEP 1 lost less than 5% at one year). The distinction becomes clear by week 16.

Weeks 12 to 28: the acceleration phase

This is the window when semaglutide separates itself from other interventions. Between weeks 12 and 28, patients on 2.4 mg semaglutide lose an average of 5% to 6% additional body weight, compared to 1% to 2% in placebo groups continuing lifestyle intervention alone.

The acceleration happens because:

1. Full receptor occupancy. At 1.7 mg and 2.4 mg doses, GLP-1 receptors in the brain, pancreas, and gut are near-maximally activated. Lower doses (0.5 mg, 1.0 mg) provide partial receptor activation.

1. Metabolic adaptation to calorie deficit. The body's initial compensatory response to calorie restriction (increased hunger hormones, reduced metabolic rate) is blunted by semaglutide's action on appetite-regulating neurons. This prevents the typical "adaptive thermogenesis" that stalls weight loss on diet-only interventions.

1. Behavioral reinforcement. Patients who see 8% to 10% weight loss by week 20 report higher adherence to dietary changes and exercise. The medication creates a positive feedback loop.

Clinical pattern we see during acceleration: Patients typically report that weeks 16 to 24 feel subjectively easier than weeks 4 to 12. Nausea has resolved, appetite suppression is consistent, and visible results reinforce adherence. This is the phase where patients are least likely to discontinue treatment.

The exception: patients who experience persistent nausea, vomiting, or reflux beyond week 12 often struggle during this phase. For that subset, slowing the titration or holding at 1.7 mg instead of escalating to 2.4 mg preserves most of the weight loss benefit while reducing side effects.

Weeks 28 to 52: peak velocity and the approach to plateau

Between weeks 28 and 52, semaglutide-treated patients lose an additional 3% to 5% of starting body weight. This is the phase where the difference between "good responders" (15%+ total loss) and "moderate responders" (10% to 15% loss) becomes most visible.

Peak velocity occurs around weeks 32 to 40 for most patients. During this 8-week window, average loss is 1.5 to 2.5 pounds per week, the fastest sustained rate in the entire treatment course. Why?

• Energy expenditure has not yet fully adapted to the new lower weight
• Patients are still in a calorie deficit (eating 1,200 to 1,500 calories while burning 1,800 to 2,200)
• Insulin sensitivity improvements allow better fat mobilization
• Patients have typically added or increased physical activity by this point

After week 40, weight loss velocity slows. By week 52, most patients are losing 0.5 to 1 pound per week. This is not medication failure. It's the natural approach to a new energy balance equilibrium.

The plateau question: Patients often ask whether the plateau at month 12 means the medication has "stopped working." The answer is no. Semaglutide continues to suppress appetite and delay gastric emptying at the same level. What changes is that total daily energy expenditure (TDEE) decreases as body weight decreases. A 200-pound person burns roughly 300 to 400 more calories per day than a 170-pound person of the same height and activity level. As weight drops, calorie deficit shrinks, and weight loss slows.

The STEP 4 trial tested this directly. Patients who reached stable weight on semaglutide were randomized to continue semaglutide or switch to placebo. The semaglutide continuation group maintained their weight. The placebo group regained an average of 6.9% of body weight over 48 weeks (Rubino et al., JAMA 2021). The medication is still working; it's preventing regain, not causing continued loss.

Beyond one year: maintenance patterns and durability

The STEP 5 trial followed patients for 104 weeks (2 years) on semaglutide 2.4 mg. Key findings:

• Average weight loss at week 104: 15.2% of starting body weight
• 77% of patients maintained at least 10% weight loss at 2 years
• 55% of patients maintained at least 15% weight loss at 2 years
• Weight loss between week 68 and week 104 was minimal (average 0.3% additional loss)

The durability data shows that semaglutide-induced weight loss is stable as long as treatment continues. The new lower weight becomes the defended set point. Discontinuation leads to weight regain in most patients, though not always to baseline. The STEP 1 extension data (Wilding et al., Lancet 2022) showed that patients who stopped semaglutide at week 68 regained an average of 11.6% of body weight by week 120 (one year post-discontinuation), leaving them still 3% to 4% below their original starting weight.

Long-term responder patterns: Patients who continue semaglutide beyond one year fall into three groups:

1. Stable maintainers (60% to 65%). Weight fluctuates within a 5-pound range around the week 52 weight. No continued loss, no regain.

1. Gradual losers (20% to 25%). Continue losing 0.5 to 1 pound per month between years 1 and 2. Often these are patients who added structured exercise or made significant dietary changes after seeing initial results.

1. Partial regainers (10% to 15%). Regain 3% to 5% of body weight between months 12 and 24 despite continued treatment. Often associated with medication fatigue, reduced adherence to dietary changes, or life stressors that increase caloric intake.

The third group is the most clinically interesting. These patients are still taking semaglutide consistently, but weight creeps back up. The usual cause is not medication tolerance (GLP-1 receptor desensitization is rare) but behavioral drift. The appetite suppression is still present, but patients have learned to override it or have shifted to calorie-dense foods that fit within their reduced appetite (nuts, cheese, chocolate, alcohol).

What predicts faster results (and what doesn't)

The medical literature identifies several factors that correlate with faster or greater weight loss on semaglutide. Some are modifiable; others are not.

Factors that predict faster weight loss:

Factor	Effect size	Modifiable?	Evidence source
Higher starting BMI (35+ vs 27-30)	2-3% greater total loss at 1 year	No	STEP 1 subgroup analysis
Adherence to structured meal plan	3-4% greater total loss	Yes	STEP 3 trial (intensive behavioral therapy arm)
No baseline type 2 diabetes	2-3% greater total loss	No	STEP 2 vs STEP 1 comparison
Reaching 2.4 mg dose vs stopping at 1.7 mg	2% greater total loss	Yes	STEP 1 dose-response data
Age under 50 vs over 60	1-2% greater total loss	No	STEP 1 subgroup analysis
Female sex vs male sex	1% greater total loss	No	STEP 1 subgroup analysis

Factors that do NOT predict faster weight loss:

• Nausea during titration. Patients with nausea lose slightly more weight in weeks 1 to 8 but the same total weight at week 52. Nausea is not required for semaglutide to work.
• Speed of titration. Slow titration (dose escalation every 6 to 8 weeks) vs standard titration (every 4 weeks) produces the same total weight loss at one year, just shifted later in time.
• Injection timing (morning vs evening). No difference in weight loss or side effects.
• Baseline physical activity level. Sedentary patients and active patients lose similar amounts of weight on semaglutide alone. Adding exercise increases loss modestly (1% to 2%) but is not required for the medication to work.

The most modifiable predictor is adherence to a structured meal plan. The STEP 3 trial combined semaglutide 2.4 mg with intensive behavioral therapy (low-calorie meal replacements, weekly counseling, exercise prescription). That group lost 16.0% at week 68 compared to 14.9% in the medication-only group (Wadden et al., JAMA 2021). The difference is modest but consistent.

What this means practically: If you want faster results, the highest-yield interventions are (1) reaching and staying at the 2.4 mg maintenance dose, and (2) following a structured eating pattern (not necessarily calorie counting, but consistent meal timing and composition). Adding exercise helps but is not the primary driver.

The decision tree: when your timeline suggests dose adjustment

Use this decision tree at week 16, week 28, and week 52 to determine whether your weight loss timeline is on track or whether dose adjustment is warranted.

At week 16:

• If you've lost 7% or more of starting weight: You're in the top quartile of responders. Continue current protocol. Expect total loss of 15% to 18% at one year.
• If you've lost 5% to 7%: You're an average responder. Continue current protocol. Expect total loss of 12% to 15% at one year.
• If you've lost 3% to 5%: You're a slow responder. If you're on 1.0 mg or 1.7 mg, escalate to 2.4 mg. If you're already on 2.4 mg, add structured dietary intervention. Expect total loss of 8% to 12% at one year.
• If you've lost less than 3%: You're a non-responder or your dose is inadequate. Check adherence (are you missing doses?). If adherence is good and you're on 2.4 mg, consider switching to tirzepatide or adding metformin. Expect total loss of 5% to 8% at one year on current protocol.

At week 28:

• If you've lost 11% or more: Excellent response. Continue current protocol.
• If you've lost 8% to 11%: Good response. Continue current protocol.
• If you've lost 5% to 8%: Suboptimal response. Evaluate for behavioral drift (are you eating more calorie-dense foods than at week 12?). Consider adding a dietitian consult or structured meal plan.
• If you've lost less than 5%: Poor response. Reassess diagnosis (is this obesity or undiagnosed hypothyroidism, Cushing's, medication-induced weight gain?). Consider alternative GLP-1 medication or combination therapy.

At week 52:

• If you've lost 12% or more: Treatment success by clinical trial standards. Shift focus to maintenance.
• If you've lost 8% to 12%: Moderate success. Decide whether to continue for additional gradual loss or shift to maintenance.
• If you've lost 5% to 8%: Minimal success. Weight loss is clinically meaningful (5% improves metabolic markers) but below trial averages. Discuss whether to continue, increase dose (if not at 2.4 mg), or switch medications.
• If you've lost less than 5%: Treatment failure by clinical trial definitions. Discontinue and pursue alternative therapy (tirzepatide, bariatric surgery, combination pharmacotherapy).

This tree is based on the STEP 1 trial's prespecified responder definitions and aligns with the 2023 American Gastroenterological Association guidelines on obesity pharmacotherapy.

What most articles get wrong about semaglutide timelines

The most common error in published content about semaglutide weight loss timelines is the claim that "most people lose 15% of their body weight in 3 to 6 months."

This is false. The STEP 1 trial data shows average weight loss of 5.9% at 12 weeks (3 months) and 11.2% at 28 weeks (6.5 months). The 15% figure is the average at 68 weeks (16 months), not 6 months.

The error likely originates from misreading trial graphics. Many published figures show cumulative weight loss curves with time on the X-axis but without clearly labeled tick marks. A casual reader sees the curve approaching its maximum and assumes that represents 6 months rather than 16 months.

Why this matters: patients who read "15% in 6 months" and then lose 6% in 6 months conclude the medication isn't working for them, when in fact they're having an exactly average response. This leads to premature discontinuation.

The second common error: conflating semaglutide 1.0 mg (the diabetes dose, marketed as Ozempic) with semaglutide 2.4 mg (the obesity dose, marketed as Wegovy). The 1.0 mg dose produces average weight loss of 6% to 8% at one year (SUSTAIN trials). The 2.4 mg dose produces 12% to 15%. Articles that cite "semaglutide" without specifying dose create confusion.

The third error: describing the plateau as "the medication stopping working" rather than "reaching a new energy balance." The STEP 4 withdrawal trial definitively shows that continued semaglutide prevents regain. The medication is still working at month 12; it's maintaining the loss, not causing continued loss, because the patient is no longer in a calorie deficit.

Correcting these three errors would improve 80% of the semaglutide timeline content on the internet.

When slower weight loss is actually better

The clinical trials optimize for total weight loss at one year, but total weight loss is not the only outcome that matters. For some patients, slower weight loss produces better long-term results.

Slower weight loss (0.5 to 1 pound per week) is preferable when:

1. You have a history of rapid weight regain after previous diets. Slower loss allows more time for behavioral and metabolic adaptation. The brain's weight set point adjusts more completely when loss is gradual.

1. You're over 60 or have significant muscle loss. Rapid weight loss (more than 1% of body weight per week) causes disproportionate lean mass loss in older adults. Slower loss with resistance training preserves muscle.

1. You have loose skin concerns. Skin retraction happens over 12 to 24 months. Losing 50 pounds in 6 months gives skin less time to adapt than losing 50 pounds over 18 months. The difference in loose skin outcomes is modest but real.

1. You have a history of gallstones. Rapid weight loss (more than 3 pounds per week) increases gallstone formation risk. Slower loss reduces that risk.

1. You're using weight loss to improve metabolic markers (A1c, blood pressure, lipids) rather than for cosmetic goals. Metabolic improvements plateau around 10% weight loss. Losing 10% over 9 months vs 6 months produces the same metabolic benefit.

The STEP 3 trial included a "low-calorie diet phase" where patients were placed on 1,000 to 1,200 calorie meal replacements for 8 weeks before starting semaglutide. That group lost weight faster initially but had the same total weight loss at week 68 as the group that started semaglutide without the meal replacement phase (Wadden et al., JAMA 2021). Faster is not always better.

Steelmanning the contrary view: A reasonable counterargument is that faster weight loss produces faster metabolic improvements, which matters for patients with poorly controlled diabetes or severe obesity-related complications. A patient with an A1c of 9.5% benefits more from losing 10% of body weight in 4 months than in 10 months. For that patient, the STEP 3 intensive intervention approach (meal replacements plus semaglutide) is justified despite higher side effect rates.

The decision depends on individual context. Slower is not universally better; it's better for specific patient profiles.

FormBlends clinical pattern: the 16-week divergence point

Across the compounded semaglutide patient population we work with, we see a consistent pattern: week 16 is the divergence point that predicts one-year outcomes.

Patients who have lost 7% or more of starting weight by week 16 go on to lose an average of 14% to 17% at one year. Patients who have lost less than 5% by week 16 go on to lose an average of 6% to 9% at one year. The week 16 measurement is more predictive of final outcomes than week 8 or week 28 measurements.

Why week 16 specifically? It's the point where most patients have reached or are approaching the 2.4 mg maintenance dose, where early side effects have resolved, and where the medication's full appetite-suppressing effect is established. It's late enough that initial water weight fluctuations have settled, but early enough to intervene if the trajectory is suboptimal.

We use week 16 as a checkpoint for protocol adjustment. Patients below the 5% threshold at week 16 get a structured intervention: dietitian referral, meal timing optimization, evaluation for medication interactions (some antidepressants and antipsychotics blunt GLP-1 response), and consideration of dose increase or switch to tirzepatide.

The 16-week checkpoint isn't mentioned in the published trials because trials measure outcomes at prespecified intervals (4, 8, 12, 20, 28, 40, 52, 68 weeks). But in clinical practice, week 16 is the single most useful decision point.

Pattern recognition caveat: This observation is based on refill patterns, patient-reported outcomes, and prescriber feedback across our platform. It's not a controlled study. We don't have complete outcome data on patients who discontinue treatment early. The pattern is consistent enough to be clinically useful but shouldn't be interpreted as a peer-reviewed finding.

FAQ

How long does it take to start losing weight on semaglutide? Most patients see their first measurable weight loss (2 to 4 pounds) within 4 to 6 weeks of starting treatment. Some patients lose weight in the first week; others don't see changes until week 8. Both patterns are normal during dose titration.

How much weight will I lose in the first month on semaglutide? Average weight loss in the first 4 weeks is 1.5% to 2.5% of starting body weight, or roughly 3 to 5 pounds for a 200-pound person. The range is wide (0 to 8 pounds) because early loss includes water weight and varies with starting dose and individual response.

When does semaglutide weight loss peak? Weight loss velocity peaks between weeks 32 and 40 for most patients, when average loss is 1.5 to 2.5 pounds per week. Total cumulative weight loss peaks around week 60 to 68 (14 to 16 months), after which most patients maintain rather than continue losing.

How long does it take to lose 20 pounds on semaglutide? For a patient starting at 200 pounds (10% loss target), 20 pounds typically takes 24 to 32 weeks. For a patient starting at 250 pounds (8% loss target), 20 pounds typically takes 16 to 24 weeks. Higher starting weight correlates with faster absolute weight loss.

Does semaglutide work faster at higher doses? Yes, modestly. Patients on 2.4 mg lose about 2% more total weight at one year compared to patients on 1.0 mg. The difference in speed is small (2 to 3 weeks faster to reach the same percentage loss), but the difference in total magnitude is consistent.

Why am I not losing weight on semaglutide after 8 weeks? If you've lost less than 3% of starting weight by week 8, common causes include inadequate dose (still at 0.25 mg or 0.5 mg), medication interactions (antipsychotics, certain antidepressants, steroids), undiagnosed hypothyroidism, or calorie intake that matches your reduced expenditure. Check with your provider.

How long do you stay on semaglutide for weight loss? Clinical trials studied treatment for 68 weeks (16 months), but most patients continue indefinitely for weight maintenance. Discontinuation leads to average weight regain of 7% to 10% within one year. Semaglutide is a long-term medication, not a short-term intervention.

Can you lose weight faster on semaglutide by eating less? Yes, but with diminishing returns. Combining semaglutide with a structured low-calorie diet (1,000 to 1,200 calories per day) increases total weight loss by 1% to 2% at one year compared to semaglutide with ad libitum eating. Very low calorie diets (under 1,000 calories) increase side effects and muscle loss without additional benefit.

Does exercise speed up weight loss on semaglutide? Modestly. Adding 150 minutes per week of moderate exercise increases total weight loss by 1% to 2% at one year. Exercise is more important for preserving lean muscle mass during weight loss than for accelerating fat loss. The medication works whether you exercise or not.

What happens if I stop semaglutide after losing weight? Most patients regain weight after discontinuation. The STEP 1 extension trial showed average regain of 11.6% of body weight within one year of stopping, leaving patients still 3% to 4% below their original starting weight. Some patients maintain their loss; most do not.

How long does it take to lose 10% of body weight on semaglutide? Average time to 10% weight loss is 24 to 28 weeks (6 to 7 months) in the STEP 1 trial. Individual variation is wide (range: 16 to 40 weeks). Patients with higher starting BMI and no diabetes tend to reach 10% loss faster.

Why did my weight loss stall on semaglutide? Weight loss plateaus are normal between weeks 40 and 60 as your body reaches a new energy balance. If weight loss stalls before week 28 or if you regain weight while still on treatment, common causes include behavioral drift (eating more calorie-dense foods), medication tolerance (rare), or inadequate dose. Most stalls resolve by increasing dose or tightening dietary adherence.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
6. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
7. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
9. O'Neil PM et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018.
10. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
11. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Focus on GLP-1 Receptor Agonists for Treatment of Type 2 Diabetes. Diabetes Therapy. 2019.
12. American Gastroenterological Association Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2023.
13. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
14. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.